CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) CEO Josh Mandel-Brehm acquired 6,551 shares of the stock in a transaction dated Monday, August 3rd. CAMP4 Therapeutics Stock Down 3.6%Shares of CAMP traded down $0.15 during trading hours on Wednesday, reaching $4.01. Get CAMP4 Therapeutics alerts:CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Featured ArticlesReceive News & Ratings for CAMP4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.